Progress Continues in Company's Four Business Units:
- Urology : Urinary catheter blockage and encrustation trial enrolling patients. Results are expected H2-2011.
- Hospital Infection : NovaBay's FDA – 510(k) cleared NeutroPhase ® is expected to be manufactured under FDA guidelines in 2011 and will be available in early 2012 to the 6 million patients suffering from chronic non-healing wounds such as diabetic, pressure, and venous stasis ulcers. Revenue is expected in 2012.
- Dermatology : Galderma, S.A. moving rapidly to begin expanded Phase 2b impetigo trial with our lead Aganocide in H1-2011. Results expected in H2-2011.
- Ophthalmology : Results from Alcon's Phase 2 proof of concept, viral conjunctivitis study expected in Q2-2011.